Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Diabetes & Obesity Care Operating Profit

Diabetes & Obesity Care Operating Profit % Chg.

Diabetes & Obesity Care Operating Profit Common Size

Rare Disease Operating Profit

Rare Disease Operating Profit % Chg.

Rare Disease Operating Profit Common Size

Other EBIT

Other EBIT % Chg.

Other EBIT Common Size

Total EBIT

Total EBIT Common Size

Total EBIT % Chg.

US Revenue

US Revenue % Chg.

US Revenue Common Size

EUCAN Revenue

EUCAN Revenue % Chg.

EUCAN Revenue Common Size

Emerging Markets Revenue

Emerging Markets Revenue % Chg.

Emerging Markets Revenue Common Size

APAC Revenue

APAC Revenue % Chg.

APAC Revenue Common Size

China Revenue

China Revenue % Chg.

China Revenue Common Size

Total International Revenue

Total International Revenue % Chg.

Total International Revenue Common Size

Total Revenue by Geography

Total Revenue by Geography Common Size

Total Revenue by Geography % Chg.

Revenue by Geography

US Revenue (Pre-FY2024 Reporting)

US Revenue (Pre-FY2024 Reporting) % Chg.

US Revenue (Pre-FY2024 Reporting) Common Size

Other North American Operations (NAO) Revenue

Other North American Operations (NAO) Revenue % Chg.

Other North American Operations (NAO) Revenue Common Size

Total North American Operations (NAO) Revenue

Total North American Operations (NAO) Revenue % Chg.

Total North American Operations (NAO) Revenue Common Size

EMEA Revenue

EMEA Revenue % Chg.

EMEA Revenue Common Size

China Revenue (Pre-FY2024 Reporting)

China Revenue (Pre-FY2024 Reporting) % Chg.

China Revenue (Pre-FY2024 Reporting) Common Size

Rest of World Revenue

Rest of World Revenue % Chg.

Rest of World Revenue Common Size

Other Revenue by Geography

Other Revenue by Geography % Chg.

Other Revenue by Geography Common Size

Rybelsus Revenue

Rybelsus Revenue % Chg.

Rybelsus Revenue Common Size

Ozempic Revenue

Ozempic Revenue % Chg.

Ozempic Revenue Common Size

Victoza Revenue

Victoza Revenue % Chg.

Victoza Revenue Common Size

Total GLP-1 Revenue

Total GLP-1 Revenue % Chg.

Total GLP-1 Revenue Common Size

Long-Acting Insulin Revenue

Long-Acting Insulin Revenue % Chg.

Long-Acting Insulin Revenue Common Size

Premix Insulin Revenue

Premix Insulin Revenue % Chg.

Premix Insulin Revenue Common Size

Fast-Acting Insulin Revenue

Fast-Acting Insulin Revenue % Chg.

Fast-Acting Insulin Revenue Common Size

Human Insulin Revenue

Human Insulin Revenue % Chg.

Human Insulin Revenue Common Size

Total Insulin Revenue

Total Insulin Revenue % Chg.

Total Insulin Revenue Common Size

Other Diabetes Care Revenue

Other Diabetes Care Revenue % Chg.

Other Diabetes Care Revenue Common Size

Total Diabetes Care Revenue

Total Diabetes Care Revenue % Chg.

Total Diabetes Care Revenue Common Size

Wegovy Revenue

Wegovy Revenue % Chg.

Wegovy Revenue Common Size

Saxenda Revenue

Saxenda Revenue % Chg.

Saxenda Revenue Common Size

Total Obesity Care Revenue

Total Obesity Care Revenue % Chg.

Total Obesity Care Revenue Common Size

Diabetes & Obesity Care Revenue

Diabetes & Obesity Care Revenue % Chg.

Diabetes & Obesity Care Revenue Common Size

Rare Blood Disorders Revenue

Rare Blood Disorders Revenue % Chg.

Rare Blood Disorders Revenue Common Size

Rare Endocrine Disorders Revenue

Rare Endocrine Disorders Revenue % Chg.

Rare Endocrine Disorders Revenue Common Size

Other Rare Disease Revenue

Other Rare Disease Revenue % Chg.

Other Rare Disease Revenue Common Size

Rare Disease Revenue

Rare Disease Revenue % Chg.

Rare Disease Revenue Common Size

Total Revenue

Total Revenue Common Size

Total Revenue % Chg.

Revenue	Sep '25	Jun '25
Rybelsus Revenue	3,728.5	3,744.8
Ozempic Revenue	20,306.9	20,237.7
Victoza Revenue	632.9	497.8
Total GLP-1 Revenue	24,668.3	24,480.3
Long-Acting Insulin Revenue	3,021.7	3,007.5
Premix Insulin Revenue	1,678.6	1,710.6
Fast-Acting Insulin Revenue	3,101.5	3,120
Human Insulin Revenue	946.3	1,025.6
Total Insulin Revenue	8,748.1	8,863.7
Other Diabetes Care Revenue	292.5	304.9
Total Diabetes Care Revenue	33,709	33,648.9
Wegovy Revenue	12,127.2	11,692.9
Saxenda Revenue	660.6	780.8
Total Obesity Care Revenue	12,787.7	12,473.7
Diabetes & Obesity Care Revenue	46,496.7	46,122.6
Rare Blood Disorders Revenue	1,939.8	1,958.3
Rare Endocrine Disorders Revenue	951.2	928.7
Other Rare Disease Revenue	248.8	241.9
Rare Disease Revenue	3,139.8	3,128.9
Total Revenue	49,636.5	49,251.5

Revenue by Geography	Sep '25	Jun '25
US Revenue	28,434.4	28,340.5
EUCAN Revenue	10,128.1	9,746.1
Emerging Markets Revenue	4,743.9	5,028.9
APAC Revenue	3,310.8	3,145.1
China Revenue	3,019.4	2,990.7
Total International Revenue	21,202.1	20,910.9
Total Revenue by Geography	49,636.5	49,251.5

Revenue by Geography	Sep '25	Jun '25
US Revenue (Pre-FY2024 Reporting)	24,600.5	28,340.5
Other North American Operations (NAO) Revenue	—	—
Total North American Operations (NAO) Revenue	—	—
EMEA Revenue	—	—
China Revenue (Pre-FY2024 Reporting)	3,019.4	2,990.7
Rest of World Revenue	—	—
Other Revenue by Geography	46,617.2	46,260.7
Total Revenue by Geography	49,636.5	49,251.5

EBIT	Sep '25	Jun '25
Diabetes & Obesity Care Operating Profit	20,672.9	22,214.1
Rare Disease Operating Profit	191.1	332.2
Total EBIT	20,864	22,546.3